Rui Wang

Rui Wang practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Rui Wang's NPI, 1942576954, was assigned on March 25, 2012. Rui Wang graduated from West China University of Medical Sciences in 1996. Rui Wang holds New Jersey license 25MA10351400.

Rui Wang's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Rui Wang's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Rui Wang to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Rui Wang practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Rui Wang's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Rui Wang is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Rui Wang's licenses on file in 3 states: New Jersey, Florida and New York.

Dmand AI lists breast cancer among the conditions Rui Wang treats.

CMS data shows 489 Medicare services from Rui Wang across 3 procedure codes in 2024, all of them office visits, for 189 Medicare patients. Medicare paid $40,696 for them. Every service was in an office.

CMS counts 189 Medicare patients who saw Rui Wang in 2024. The largest group is 65 to 74, with 110 patients. 75% of them have cancer, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.65, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Rui Wang's median patient age at 69, with 96% women.

In 2024, Rui Wang wrote 443 Medicare Part D claims for 168 patients. 85% of them were for generic drugs. CMS names the drug for 332 of them, across 7 drugs with 11 or more claims each, at $467,609 in total drug cost. In 2023, CMS named 474 claims across 9 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Rui Wang for performance year 2024, reported as part of a group. Rui Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Rui Wang as offering telehealth.

Dmand AI links 16 papers to Rui Wang, published from 2015 to 2022. 2015 was the busiest year, with 2. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Receptor, ErbB-2. Rui Wang has published most often in Clin Cancer Res. Rui Wang's most frequent co-authors are Shanu Modi, MD, Sarat Chandarlapaty, MD, PhD and Clifford A. Hudis, MD.

Dmand AI links Rui Wang to 1 clinical trial. Conditions studied include Respiratory Distress Syndrome and Respiration Disorders.

CMS Open Payments shows 3 general payments to Rui Wang from 3 drug and device companies from 2018 to 2024. Food and beverage make up the largest share, 82% of the total. Puma Biotechnology, Inc. paid the most, $37.

Rui Wang graduated from West China University of Medical Sciences in 1996.

Rui Wang is in network with 10 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. PPO plans come from the most carriers, 6. Check the plan with the practice before a visit.